Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 26 Apr 2023
Researchers from McGill University found that nurses who receive 40 minutes of bright light exposure prior to their night shifts experience less fatigue and commit fewer mistakes. Following their shifts, the nurses also slept better.
Read Full NewsImproving Diabetic Macular Edema Care in Native American Communities: Real-World Insights and Culturally Responsive Approaches
Targeting the PI3K/AKT/PTEN Pathway to Optimize Treatment for HR+/HER2- Breast Cancer
Navigating Treatment-Associated Adverse Events and Patient-Centered Supportive Care in HR+/HER2- Breast Cancer
Optimizing Safe Administration of Novel Infusion Therapies in HR+/HER2- Advanced Breast Cancer
Optimizing Treatment Sequencing in Endocrine-Refractory HR+/HER2- Breast Cancer
Evaluating the Latest Evidence on Emerging Somatostatin Receptor Ligands for Acromegaly
Navigating Advances in Cystic Fibrosis Care
1.
How access to specialized cancer centers affects glioblastoma outcomes
2.
Drug-chemo combo increases cancer treatment efficacy
3.
Five new papers highlight cancer inequities, challenges and opportunities in South Asia
4.
3D virtual staining technology enables non-invasive observation of cancer tissue
5.
Prior authorizations draining time, energy from many cancer patients
1.
Transplant Oncology and Anti-Cancer Immunosuppressants: The Evolution of a Paradigm in Cancer Care
2.
Unlocking The Causes And Risk Factors Of Breast Cancer
3.
Glycopyrrolate: The Secret Weapon for Excessive Sweating
4.
Understanding Dasatinib: A Promising Drug for Cancer Treatment
5.
Unlocking the Mysteries of Synovial Sarcoma: A New Hope for Treatment
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Benefits of Treatment with CDK4/6 Inhibitors in HR+/HER2- aBC in Clinical Trials and the Real World
2.
Unmet Needs in ALK Positive NSCLC- The Challenges in the Current Care
3.
Navigating the Complexities of Ph Negative ALL - Part XII
4.
Updates on the First Line Management of ALK+ NSCLC
5.
Efficient Management of First line ALK-rearranged NSCLC - Part VII
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2025 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge